Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

GOVX vs NVAX vs IOVA vs DVAX vs SIGA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GOVX
GeoVax Labs, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$2M
5Y Perf.-96.3%
NVAX
Novavax, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.50B
5Y Perf.-91.5%
IOVA
Iovance Biotherapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.27B
5Y Perf.-89.2%
DVAX
Dynavax Technologies Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$1.82B
5Y Perf.+258.6%
SIGA
SIGA Technologies, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$339M
5Y Perf.-31.1%

GOVX vs NVAX vs IOVA vs DVAX vs SIGA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GOVX logoGOVX
NVAX logoNVAX
IOVA logoIOVA
DVAX logoDVAX
SIGA logoSIGA
IndustryBiotechnologyBiotechnologyBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$2M$1.50B$1.27B$1.82B$339M
Revenue (TTM)$2M$596M$286M$331M$94M
Net Income (TTM)$-21M$-88M$-354M$-43M$-4.04T
Gross Margin100.0%84.6%114.5%83.2%61.8%
Operating Margin-8.7%-11.2%-127.2%3.2%27.7%
Forward P/E3.6x31.6x2.8x
Total Debt$843.17B$249M$48M$254M$595K
Cash & Equiv.$6M$241M$163M$96M$155M

GOVX vs NVAX vs IOVA vs DVAX vs SIGALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GOVX
NVAX
IOVA
DVAX
SIGA
StockSep 20May 26Return
GeoVax Labs, Inc. (GOVX)1003.7-96.3%
Novavax, Inc. (NVAX)1008.5-91.5%
Iovance Biotherapeu… (IOVA)10010.8-89.2%
Dynavax Technologie… (DVAX)100358.6+258.6%
SIGA Technologies, … (SIGA)10068.9-31.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: GOVX vs NVAX vs IOVA vs DVAX vs SIGA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GOVX and DVAX are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Dynavax Technologies Corporation is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. SIGA and NVAX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
GOVX
GeoVax Labs, Inc.
The Momentum Pick

GOVX has the current edge in this matchup, primarily because of its strength in momentum and efficiency.

  • +89.4% vs SIGA's +1.5%
  • -0.0% ROA vs IOVA's -38.8%, ROIC -0.0% vs -48.9%
Best for: momentum and efficiency
NVAX
Novavax, Inc.
The Growth Play

NVAX is the clearest fit if your priority is growth exposure.

  • Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
  • 64.7% revenue growth vs GOVX's -37.1%
Best for: growth exposure
IOVA
Iovance Biotherapeutics, Inc.
The Growth Angle

Among these 5 stocks, IOVA doesn't own a clear edge in any measured category.

Best for: healthcare exposure
DVAX
Dynavax Technologies Corporation
The Defensive Pick

DVAX is the #2 pick in this set and the best alternative if defensive is your priority.

  • Beta 0.75, current ratio 10.80x
  • -13.1% margin vs SIGA's -43K%
  • Beta 0.75 vs GOVX's 2.23
Best for: defensive
SIGA
SIGA Technologies, Inc.
The Income Pick

SIGA ranks third and is worth considering specifically for income & stability and long-term compounding.

  • Dividend streak 4 yrs, beta 1.15, yield 12.7%
  • 7.6% 10Y total return vs DVAX's 2.9%
  • Lower volatility, beta 1.15, Low D/E 0.3%, current ratio 11.83x
  • Lower P/E (2.8x vs 31.6x)
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNVAX logoNVAX64.7% revenue growth vs GOVX's -37.1%
ValueSIGA logoSIGALower P/E (2.8x vs 31.6x)
Quality / MarginsDVAX logoDVAX-13.1% margin vs SIGA's -43K%
Stability / SafetyDVAX logoDVAXBeta 0.75 vs GOVX's 2.23
DividendsSIGA logoSIGA12.7% yield; 4-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)GOVX logoGOVX+89.4% vs SIGA's +1.5%
Efficiency (ROA)GOVX logoGOVX-0.0% ROA vs IOVA's -38.8%, ROIC -0.0% vs -48.9%

GOVX vs NVAX vs IOVA vs DVAX vs SIGA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GOVXGeoVax Labs, Inc.
FY 2022
NIH Grants
100.0%$81,526
NVAXNovavax, Inc.
FY 2025
Product
50.0%$685M
Nuvaxovid Sales
45.6%$625M
Supply Sales
4.4%$60M
IOVAIovance Biotherapeutics, Inc.

Segment breakdown not available.

DVAXDynavax Technologies Corporation
FY 2024
H E P L I S A V B
96.8%$268M
Other Revenue
3.2%$9M
SIGASIGA Technologies, Inc.
FY 2025
Product Sales and Supportive Services
93.1%$88M
Research and Development
6.9%$7M

GOVX vs NVAX vs IOVA vs DVAX vs SIGA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLDVAXLAGGINGIOVA

Income & Cash Flow (Last 12 Months)

Evenly matched — IOVA and DVAX and SIGA each lead in 2 of 6 comparable metrics.

NVAX is the larger business by revenue, generating $596M annually — 239.6x GOVX's $2M. DVAX is the more profitable business, keeping -13.1% of every revenue dollar as net income compared to SIGA's -43117.4%. On growth, IOVA holds the edge at +44.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGOVX logoGOVXGeoVax Labs, Inc.NVAX logoNVAXNovavax, Inc.IOVA logoIOVAIovance Biotherap…DVAX logoDVAXDynavax Technolog…SIGA logoSIGASIGA Technologies…
RevenueTrailing 12 months$2M$596M$286M$331M$94M
EBITDAEarnings before interest/tax-$22M-$47M-$330M$19M$26M
Net IncomeAfter-tax profit-$21M-$88M-$354M-$43M-$4.04T
Free Cash FlowCash after capex-$21M-$96M-$305M$81M$33M
Gross MarginGross profit ÷ Revenue+100.0%+84.6%+114.5%+83.2%+61.8%
Operating MarginEBIT ÷ Revenue-8.7%-11.2%-127.2%+3.2%+27.7%
Net MarginNet income ÷ Revenue-8.6%-14.7%-123.9%-13.1%-43117.4%
FCF MarginFCF ÷ Revenue-8.6%-16.1%-106.8%+24.4%+35.2%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%-79.1%+44.8%+17.7%-11.3%
EPS Growth (YoY)Latest quarter vs prior year+86.9%-102.0%+47.2%+90.9%
Evenly matched — IOVA and DVAX and SIGA each lead in 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — GOVX and SIGA each lead in 2 of 6 comparable metrics.

At 3.6x trailing earnings, NVAX trades at a 95% valuation discount to DVAX's 77.5x P/E. On an enterprise value basis, NVAX's 2.6x EV/EBITDA is more attractive than DVAX's 503.2x.

MetricGOVX logoGOVXGeoVax Labs, Inc.NVAX logoNVAXNovavax, Inc.IOVA logoIOVAIovance Biotherap…DVAX logoDVAXDynavax Technolog…SIGA logoSIGASIGA Technologies…
Market CapShares × price$2M$1.5B$1.3B$1.8B$339M
Enterprise ValueMkt cap + debt − cash$843.2B$1.5B$1.2B$2.0B$185M
Trailing P/EPrice ÷ TTM EPS-0.08x3.63x-3.26x77.50x14.33x
Forward P/EPrice ÷ next-FY EPS est.31.59x2.78x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple2.56x503.23x7.60x
Price / SalesMarket cap ÷ Revenue0.68x1.34x4.82x6.56x3.58x
Price / BookPrice ÷ Book value/share0.00x1.82x3.46x1.70x
Price / FCFMarket cap ÷ FCF30.24x6.96x
Evenly matched — GOVX and SIGA each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

SIGA leads this category, winning 4 of 9 comparable metrics.

GOVX delivers a -0.0% return on equity — every $100 of shareholder capital generates $-0 in annual profit, vs $-50 for IOVA. SIGA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DVAX's 0.43x. On the Piotroski fundamental quality scale (0–9), DVAX scores 6/9 vs GOVX's 4/9, reflecting solid financial health.

MetricGOVX logoGOVXGeoVax Labs, Inc.NVAX logoNVAXNovavax, Inc.IOVA logoIOVAIovance Biotherap…DVAX logoDVAXDynavax Technolog…SIGA logoSIGASIGA Technologies…
ROE (TTM)Return on equity-0.0%-50.2%-8.1%-10.7%
ROA (TTM)Return on assets-0.0%-7.4%-38.8%-4.6%-7.4%
ROICReturn on invested capital-0.0%-48.9%-0.4%+33.7%
ROCEReturn on capital employed-0.0%+100.4%-51.6%-0.4%+11.3%
Piotroski ScoreFundamental quality 0–945565
Debt / EquityFinancial leverage0.22x0.07x0.43x0.00x
Net DebtTotal debt minus cash$843.2B$8M-$115M$159M-$154M
Cash & Equiv.Liquid assets$6M$241M$163M$96M$155M
Total DebtShort + long-term debt$843.2B$249M$48M$254M$595,169
Interest CoverageEBIT ÷ Interest expense-5.10x-5.28x
SIGA leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DVAX leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in DVAX five years ago would be worth $15,800 today (with dividends reinvested), compared to $197 for GOVX. Over the past 12 months, GOVX leads with a +89.4% total return vs SIGA's +1.5%. The 3-year compound annual growth rate (CAGR) favors DVAX at 12.4% vs GOVX's -43.9% — a key indicator of consistent wealth creation.

MetricGOVX logoGOVXGeoVax Labs, Inc.NVAX logoNVAXNovavax, Inc.IOVA logoIOVAIovance Biotherap…DVAX logoDVAXDynavax Technolog…SIGA logoSIGASIGA Technologies…
YTD ReturnYear-to-date+750.2%+29.5%+40.9%+0.8%-15.0%
1-Year ReturnPast 12 months+89.4%+55.1%+13.4%+59.5%+1.5%
3-Year ReturnCumulative with dividends-82.4%+23.9%-49.9%+42.1%+22.2%
5-Year ReturnCumulative with dividends-98.0%-94.8%-87.6%+58.0%+1.4%
10-Year ReturnCumulative with dividends-96.0%-90.4%-34.3%+2.9%+764.0%
CAGR (3Y)Annualised 3-year return-43.9%+7.4%-20.6%+12.4%+6.9%
DVAX leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

DVAX leads this category, winning 2 of 2 comparable metrics.

DVAX is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than GOVX's 2.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DVAX currently trades 98.5% from its 52-week high vs GOVX's 40.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGOVX logoGOVXGeoVax Labs, Inc.NVAX logoNVAXNovavax, Inc.IOVA logoIOVAIovance Biotherap…DVAX logoDVAXDynavax Technolog…SIGA logoSIGASIGA Technologies…
Beta (5Y)Sensitivity to S&P 5002.23x2.11x2.01x0.75x1.15x
52-Week HighHighest price in past year$4.40$11.97$5.63$15.73$9.62
52-Week LowLowest price in past year$0.12$5.80$1.64$9.20$4.29
% of 52W HighCurrent price vs 52-week peak+40.0%+77.1%+63.1%+98.5%+49.2%
RSI (14)Momentum oscillator 0–10067.864.463.175.747.0
Avg Volume (50D)Average daily shares traded217K4.4M16.2M5.7M688K
DVAX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

SIGA leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NVAX as "Buy", IOVA as "Buy", DVAX as "Buy", SIGA as "Buy". Consensus price targets imply 95.0% upside for NVAX (target: $18) vs -43.7% for IOVA (target: $2). SIGA is the only dividend payer here at 12.73% yield — a key consideration for income-focused portfolios.

MetricGOVX logoGOVXGeoVax Labs, Inc.NVAX logoNVAXNovavax, Inc.IOVA logoIOVAIovance Biotherap…DVAX logoDVAXDynavax Technolog…SIGA logoSIGASIGA Technologies…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$18.00$2.00$27.00
# AnalystsCovering analysts2320111
Dividend YieldAnnual dividend ÷ price+12.7%
Dividend StreakConsecutive years of raises114
Dividend / ShareAnnual DPS$0.60
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.3%0.0%+5.5%0.0%
SIGA leads this category, winning 1 of 1 comparable metric.
Key Takeaway

SIGA leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). DVAX leads in 2 (Total Returns, Risk & Volatility). 2 tied.

Best OverallDynavax Technologies Corpor… (DVAX)Leads 2 of 6 categories
Loading custom metrics...

GOVX vs NVAX vs IOVA vs DVAX vs SIGA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is GOVX or NVAX or IOVA or DVAX or SIGA a better buy right now?

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -37. 1% for GeoVax Labs, Inc. (GOVX). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GOVX or NVAX or IOVA or DVAX or SIGA?

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Dynavax Technologies Corporation at 77. 5x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — GOVX or NVAX or IOVA or DVAX or SIGA?

Over the past 5 years, Dynavax Technologies Corporation (DVAX) delivered a total return of +58.

0%, compared to -98. 0% for GeoVax Labs, Inc. (GOVX). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus GOVX's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GOVX or NVAX or IOVA or DVAX or SIGA?

By beta (market sensitivity over 5 years), Dynavax Technologies Corporation (DVAX) is the lower-risk stock at 0.

75β versus GeoVax Labs, Inc. 's 2. 23β — meaning GOVX is approximately 199% more volatile than DVAX relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 43% for Dynavax Technologies Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — GOVX or NVAX or IOVA or DVAX or SIGA?

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -37. 1% for GeoVax Labs, Inc. (GOVX). On earnings-per-share growth, the picture is similar: Dynavax Technologies Corporation grew EPS 503. 2% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, GOVX leads at 212. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GOVX or NVAX or IOVA or DVAX or SIGA?

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -862. 3% for GeoVax Labs, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -869. 3% for GOVX. At the gross margin level — before operating expenses — GOVX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GOVX or NVAX or IOVA or DVAX or SIGA more undervalued right now?

On forward earnings alone, SIGA Technologies, Inc.

(SIGA) trades at 2. 8x forward P/E versus 31. 6x for Dynavax Technologies Corporation — 28. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVAX: 95. 0% to $18. 00.

08

Which pays a better dividend — GOVX or NVAX or IOVA or DVAX or SIGA?

In this comparison, SIGA (12.

7% yield) pays a dividend. GOVX, NVAX, IOVA, DVAX do not pay a meaningful dividend and should not be held primarily for income.

09

Is GOVX or NVAX or IOVA or DVAX or SIGA better for a retirement portfolio?

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). GeoVax Labs, Inc. (GOVX) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, GOVX: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GOVX and NVAX and IOVA and DVAX and SIGA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GOVX is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock; IOVA is a small-cap high-growth stock; DVAX is a small-cap high-growth stock; SIGA is a small-cap deep-value stock. SIGA pays a dividend while GOVX, NVAX, IOVA, DVAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

GOVX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 60%
Run This Screen
Stocks Like

NVAX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 50%
Run This Screen
Stocks Like

IOVA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 22%
  • Gross Margin > 68%
Run This Screen
Stocks Like

DVAX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Gross Margin > 49%
Run This Screen
Stocks Like

SIGA

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 37%
  • Dividend Yield > 5.0%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GOVX and NVAX and IOVA and DVAX and SIGA on the metrics below

Revenue Growth>
%
(GOVX: -100.0% · NVAX: -79.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.